兴齐眼药(300573) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥547,493,493.82, representing a 30.54% increase compared to the same period last year[2]. - Net profit attributable to shareholders was ¥121,442,412.83, up 28.41% year-on-year[2]. - The net profit after deducting non-recurring gains and losses was ¥121,091,167.47, reflecting a 32.18% increase compared to the previous year[2]. - The basic and diluted earnings per share were both ¥0.70, a 29.63% increase from ¥0.54 in the same period last year[2]. - Total operating revenue for the current period reached ¥1,439,292,774.15, a 30.3% increase from ¥1,104,863,512.43 in the previous period[17]. - Net profit for the current period was ¥290,762,858.50, representing a 59.6% increase compared to ¥182,331,511.64 in the previous period[19]. - Basic and diluted earnings per share were both ¥1.67, up from ¥1.05 in the previous period[19]. - The company reported a total profit of ¥337,859,086.13, up from ¥202,691,425.08 in the previous period[18]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,185,769,518.15, an 8.00% increase from the previous year[3]. - The total liabilities increased to CNY 558,006,891.13 from CNY 333,923,878.75, reflecting a growth of approximately 67%[16]. - The company’s equity attributable to shareholders decreased to CNY 1,627,762,627.02 from CNY 1,689,920,857.47, a decline of about 3.7%[16]. - The company reported a total asset of CNY 2,185,769,518.15 as of September 30, 2024, an increase from CNY 2,023,844,736.22 at the beginning of the period, reflecting a growth of approximately 8%[14]. Cash Flow - Cash flow from operating activities for the year-to-date was ¥355,665,775.92, a 57.42% increase compared to the same period last year[6]. - Cash inflow from operating activities totaled ¥1,439,784,095.73, an increase from ¥1,059,437,010.02 in the previous period[20]. - The net cash flow from operating activities for Q3 2024 was CNY 355,665,775.92, an increase of 57.5% compared to CNY 225,936,626.98 in Q3 2023[21]. - The ending balance of cash and cash equivalents was CNY 503,308,315.77, up from CNY 425,355,427.88 at the end of Q3 2023, reflecting an increase of 18.3%[21]. - Cash inflow from financing activities amounted to CNY 234,207,278.57, significantly up from CNY 72,515,217.20 in Q3 2023, representing an increase of 223.5%[21]. - The net cash flow from financing activities was -CNY 218,598,586.24, worsening from -CNY 120,914,243.87 year-over-year[21]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 38,554, with a holding ratio of 28.60% for domestic individuals[7]. - Liu Jidong holds 12,473,195 shares, representing a significant portion of the company's equity[8]. - The top ten shareholders account for a total of 38.60% of the company's shares, indicating a concentrated ownership structure[9]. - The total number of shares held by the top ten unrestricted shareholders is 28,060,000, indicating a healthy liquidity position[9]. - The total number of shares held by the top ten unrestricted shareholders represents 22.50% of the total share capital, highlighting their influence on corporate governance[9]. Research and Development - The company successfully obtained drug registration certificates for two products, including atropine sulfate eye drops and bromfenac sodium eye drops, enhancing its product portfolio[12]. - The company initiated the first subject enrollment for the Phase I clinical trial of SQ-22031 eye drops, marking a significant step in its R&D efforts[13]. - Research and development expenses rose to ¥139,482,476.89, compared to ¥121,550,678.54 in the previous period, indicating a focus on innovation[17]. Other Financial Metrics - The company reported a significant increase in other income, which rose by 89.79% to ¥26,662,744.62 due to increased government subsidies[6]. - The company experienced a decrease in credit impairment losses, which were reported at -¥3,267,560.09, an improvement from -¥4,359,935.51 in the previous period[18]. - The company reported a significant increase in inventory, which rose to CNY 145,089,102.76 from CNY 136,025,273.52, an increase of approximately 6.5%[14]. - The company’s non-current assets totaled CNY 1,238,106,586.80, up from CNY 1,118,656,222.40, indicating a growth of about 10.7%[15].